All In Biotech

Drug Trial Radar · NCT06948032

Study of BLU-808 in Healthy Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLU-808 and to Assess the Drug-Drug Interaction With a CYP3A Substrate (Midazolam) and the Effect of Food in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Apr 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Aug 7, 2024

Primary completion

Jan 21, 2025

Study completion Jan 21, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • BLU-808Drug

    BLU-808 will be administered per schedule specified in the arm description.

  • PlaceboDrug

    BLU-808 matching placebo will be administered per schedule specified in the arm description.

  • MidazolamDrug

    Midazolam will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Day 20
  2. Part 2: Number of Participants With TEAEsTime frame: Up to Day 50
  3. Part 3: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t)Time frame: Up to Day 6
  4. Part 3: Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc.

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.